Clinical Trial Update: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of intratumoral LTX-315 in combination with pembrolizumab for advanced melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LTX-315 (LTX-315 peptide)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Advanced Melanoma | Phase 2 | Status: COMPLETED